Bangkok Heart Hospital and U of Pittsburgh Medical Center/McGowan Institute for Regenerative Medicine clinical trial shows that VesCell type expanded autologous blood derived stem cells utilized in intramyocardial transplantation is feasible and safe in severely ill patients with intractable heart failure in all cases of dilated cardiomyopathy (DCM) and in both first-time and “redo” ischemic cardiomyopathy (ICM) patients.
Overall ejection fraction (EF) improved significantly by 4.8% ± 7.5% at 149 ± 98 days postoperatively.
EF increased from 25.9% ± 8.6% to 28.7% ± 9.8% in dilated cardiomyopathy.
EF increased from 26.6% ± 5.8% to 33.6% ± 7.8% in ischemic cardiomyopathy.
Catch up already, would ya! Or at least, stop ignoring the safety and efficacy that other studies and trials have proved half a decade ago. -dg
Tests begin on stem cell cure for rare heart disease
Cardiologists hope new treatment can prolong the lives of patients with dilated cardiomyopathy
Stem cells in storage at the UK Stem Cell Bank in London. Photograph: Peter Macdiarmid/Reuters
Doctors are investigating whether patients with an irreversible heart condition can prolong their lives by having stem cells taken from their hip and injected into the damaged organ.
Experts at the Barts and the London Heart Attack Centre hope their work will lead to a major breakthrough for the UK’s estimated 30,000 sufferers with dilated cardiomyopathy (DCM). The rare condition causes the heart muscle wall to become thin and floppy, making the heart progressively less able to pump blood around the body. Drug treatment can be of limited benefit, and ultimately patients deteriorate to the extent that they will die unless they receive a new heart.
Researchers led by consultant cardiologist Professor Anthony Mathur are about to start the world’s first randomised control trial exploring whether stem cell therapy can repair the patient’s heart.
“We are using stem cell therapies and regenerative medicine to try to improve the heart’s function and maybe prolong their lives,” Mathur said. “These patients have such a poor prognosis, so it’s very important for them to be exposed to a potential new therapy that might change the outcome of their condition.”
He is recruiting 90 volunteers: half will have stem cells taken from the bone marrow of their hip and injected into their heart. The others will have their stem cells frozen and be given placebo injections, but will undergo the therapy if the trial is successful.
But Professor Peter Weissberg, medical director of the British Heart Foundation, said patients should not expect dramatic results soon. “At the moment, this is being done more in hope than expectation, because globally the fundamental science behind stem cells is not sufficiently mature for us to be confident of success.”